Kaposi sarcoma, renal transplant, sirolimus, sarcoma de Kaposi, trasplante renal, sirolimus,

1. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, et al. Sirolimus therapy alter early cyclosporina withdrawal reduces the
risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17:581-9.
2. Chapman J, Webster A. Cancer report, ANZDATA (Australian and New Zealand Dialysis and Transplant Registry) Registry 2004 Report. Adelaide, South Australia, 2005, Fecha de consulta: 09 de julio de 2010. Disponible en: http://www.unzdata. org.au
3. Berber I, Altaca G, Aydin C, Dural A, Kara VM, Yigit B, et al. Kaposi’s sarcoma in renal transplant patients: Predisposing factors and prognosis. Transplant Proc. 2005;37:967-8.
4. Harwood AR, Osaba D, Hafstader SL, Goldstein MB, Cardella CJ, Holecek MK, Kunynetz R, Giammarco RA. Kaposi’s sarcoma in recipients of renal transplants. Am J Med. 1979;67:759. 5. Penn I. The changing patterns of post transplant malignancies. Transplant Proc. 1991;23:1101.
6. Einollahi B. Kaposi sarcoma after kidney transplantation. Int J Kidney Dis. 2007; 1:2-11.
7. Sheil AG. Malignancy in organ transplantation recipients. Transplant
Proc. 1996;28:1162.
8. Kyllomen L, Pukkala E, Eklund B. Cancer incidence in a kidney-transplanted population. Transpl Int. 1994;7 (Suppl.1):S350-2.
9. Antman K, Chang Y. Kaposi’s sarcoma. N Engl J Med. 2000;342:1027-38.
10. Euvard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681-91.
11. Marcen R, Pascual J, Tato AM, Teruel JL, Villafruela JJ, Fernandez M, Tenorio M, Burgos FJ, Ortuño J. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant Proc. 2003;35:1714-6.
12. Quinibi W, Akhtar M, Sheth K, Ginn HE, Al-Furayh O, DeVol EB, Taher S. Kaposi’s Sarcoma: the most common tumor alter renal transplantation in Saudi Arabia. Am J Med; 84:225-32, 1988
13. Moosa MR, Walele AA, Daar AS. Renal transplantation in developing
countries. In: Morris PJ, editor. Kidney transplantation, principles and practice. Fifth edition. Philadelphia: W. B. Saunders Co.; 2001. p. 659-92.
14. Moray G, Basaran O, Yagmurdur MC, Emiroglu R, Bilgin N, Haberal Y. Immunosuppressive therapy and Kaposi’s sarcoma after kidney transplantation. Transplant Proc. 2004;36:168-70.
15. Campistol JM, Albanell J, Arns W, Boletis I, Dantal J, de Fijter JW, et al. Use of proliferation signal inhibitors in the management of post-transplant malignancies - clinical guidance. Nephrol Dial Transplant. 2007;22 (Suppl.1):
16. Penn I. Cancers in cyclosporine-treated vs. azathioprine-treated patients. Transplant Proc. 1996;28:876.
17. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8
infection. N Engl J Med. 1998;338:
18. Mayama S, Cuevas LE, Sheldon J, Omar OH, Smith DH, Okong P, Silver B, Hart CA, Schulz TF. Prevalence and transmission of Kaposi’s sarcomaassociate herpesvirus (human herpesvirus 8) in Ugandan children and adolescents. Int J Cancer. 1998;77:817-20.
19. Hladik W, Dollard SC, Mermin J, Fowlkes AL, Downing R, Amin MM, Banage F, Nzaro E, Kataaha P, Dondero TJ Pellett PE, Lackritz EM. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med. 2006;355:1331-8.
20. Ahmadpoor P. Human herpesvirus-8 and Kaposi sarcoma after kidney transplantation. Mechanism of tumor genesis. Int J Kidney Dis. 2009;3:121-6.
21. Kalt I, Masa SR, Sarid R. Linking the Kaposi’s sarcoma-associated herpesvirus (KSHV-HHV-8) to human malignancies. Methods Mol Biol. 2009;471:387-407.
22. Frances C, Marcellin AG, Legendre Ch, Chevret S, Dussaix E, Lejeune J, Euvrard S, Bigorie A, Schulz TF, Agbalika F, Lebbé C; Skin and Organ
Transplantation Group of the French Society of Dermatology. The Impact of preexisting or acquired Kaposi sarcoma herpesvirus infection in kidney transplant recipients on morbidity and survival. American Journal of Transplantation. 2009;9(11):2580-6.
23. Russo JJ, Bohenzky RA, Chien MC, Chen J, Yan M, Maddalena D, Parry JP, Peruzzi D, Edelman IS, Chang Y, Moore PS. Nucleotide sequence of the Kaposi’s sarcoma- asociate herpesvirus (HHV-8).
Proc Natl Acad Sci USA. 1996;93:
24. Lundquist A, Barre B, Bienvenu F, Hermann J, Avril S, Coqueret O. Kaposi sarcoma-associated viral cyclin K overrides cell growth inhibition mediated by oncostatin M throuhg STAT3 inhibition. Blood. 2003;101:4070-7.
25. Chatterjee M, Osborne J, Bestetti G, Chang Y, Moore PS. Viral IL-6 induced cell proliferation and immune evasion of interferon activity. Science. 2002; 298:1432-5.
26. Nakamura H, Li M, Zarycki J, Jung JU. Inhibition of p53 tumor suppressor by viral interferon regulatory factor. J Virol. 2001;75:7572-82.
27. Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, Sausville EA, Sawai ET, Molinolo A, Gutkind JS, Montaner S. The TSC2/mTOR pathway drives endotelial cell transformation induced by the Kaposi’s sarcoma-associated herpesvirus G protein coupled receptor. Cancer Cell. 2006;10:133-43.
28. Abbaszadeh S, Taheri S. Kaposi’s sarcoma after renal transplantation. Saudi J Kidney Dis Transpl. 2009; 20:775-8.
29. Firoozan A, Hosseini SM, Einollahi B, Pour-Reza-Gholi F, Nafar M, Basiri A, et al. Outcome of Kaposi’s sarcoma and graft following discontinuation of immunosuppressive drugs in renal transplant recipients. Transplant Proc. 2005;37:3061-4.
30. Huang JY, Chiang YJ, Lai PC, Shih LY, Huang CC, Chu SH, et al. Posttransplant Kaposi’s sarcoma: Report from a single center. Transplant Proc. 2004;36:
31. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M. Cyclosporine induces cancer progression by cell-autonomous mechanism. Nature. 1999;397:530-4.
32. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-ofrapamycin inhibitors is associated with reduced incidence of de novo malignancies. Transplantation. 2005; 80:883-9.
33. Stallone G, Infante B, Grandaliano G, Schena FP, Gesualdo L. Kaposi’s sarcoma and mTOR: A crossroad between viral infection neoangiogenesis and immunosuppression. Transpl Int. 2008;21:
825-32.
34. Zmonarski SC, Boratynska M, Rabczynski J, Kazimierczak K, Klinger
M. Regression of Kaposi’s sarcoma in renal graft recipients alter conversion to sirolimus treatment. Transplant Proc. 2005;37:964-6.
35. Campistol JM, Gutiérrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: A successful treatment for posttransplantation Kaposi’s sarcoma. Transplantation. 2004;77:760-2.
36. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G. Sirolimus for Kaposi’s sarcoma in renaltransplant recipients. N Engl J Med. 2005;352:1317-23.
37. Gutiérrez-Dalmau A, Sánchez-Fructuoso A, Sanz-Guajardo A, Mazuecos A, Franco A, Rial MC, et al. Efficacy of conversion to sirolimus in posttransplantation Kaposi’s sarcoma. Transplant Proc. 2005;37:3836-8.
38. Corbellino M, Bestetti G, Scalamogna C, Calattini S, Galazzi M, Meroni L, Manganaro D, Fasan M, Moroni M, Galli M, Parravicini C. Long term remission of Kaposi’s sarcoma-associated herpesvirusrelated multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood. 2001;98:3473-5.
39. Luppi M, Barozzi P, Rasini V, Riva G, Re A, Rossi G, Setti G, Sandrini S, Facchetti F, Torelli G. Severe pancytopenia and hemophagocytosis alter HHV-8 primary infection in renal transplant patient successfully treated with foscarnet. Transplantation. 2002;74:131-2.

Vol. 52 Núm. 2 (2011)